With minimally invasive bariatric surgeries becoming widely adopted alongside the rapid acceptance of newer anti-obesity medications, including GLP-1 (glucagon-like peptide) receptor agonists, there are now more viable options conferring different risks and benefits to help guide patients to achieve their goals. The gene discussed is GLP1R; the disease is obesity disorder.